Pop-BusuiRBoultonAJFeldmanEL. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–54.
2.
PapanasNZieglerD. Risk factors and comorbidities in diabetic neuropathy: an update 2015. Rev Diabet Stud. 2015;12(1-2):48–62.
3.
PafiliKPapanasNMaltezosE. Treatment of diabetic complications: how can we learn by seeking and blundering?Angiology. 2015;66(4):301–3.
4.
ZieglerDStromALobmannRReinersKRettKSchnellO. High prevalence of diagnosed and undiagnosed polyneuropathy in subjects with and without diabetes participating in a nationwide educational initiative (PROTECT study). J Diabetes Complications. 2015;29(8):998–1002.
5.
TesfayeSBoultonAJDyckPJ; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93.
6.
JaiswalMFufaaGDMartinCLPop-BusuiRNelsonRGFeldmanEL. Burden of diabetic peripheral neuropathy in Pima Indians with type 2 diabetes. Diabetes Care. 2016;39(4):e63–4.
7.
ZieglerDPapanasNRodenM; GDC Study Group. Neuropad: evaluation of three cut-off points of sudomotor dysfunction for early detection of polyneuropathy in recently diagnosed diabetes. Diabet Med. 2011;28(11):1412–5.
8.
ZieglerDPapanasNZhivovA; German Diabetes Study (GDS) Group. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454–63.
9.
PontoKAKoenigJPetoT. Prevalence of diabetic retinopathy in screening-detected diabetes mellitus: results from the Gutenberg Health Study (GHS). Diabetologia. 2016;59(9):1913–9.
10.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.
11.
ZieglerDVossARathmannW.; KORA Study Group. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia. 2015;58(5):1118–28.
12.
ZieglerDRathmannWDickhausTMeisingerCMielckA; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31(3):464–9.
13.
PapanasNVinikAIZieglerD. Neuropathy in prediabetes: does the clock start ticking early?Nat Rev Endocrinol. 2011;7(11):682–90.
14.
ZieglerDPapanasNRathmannWHeierMScheerMMeisingerC; KORA Study Group. Evaluation of the neuropad sudomotor function test as a screening tool for polyneuropathy in the elderly population with diabetes and pre-diabetes: the KORA F4 survey. Diabetes Metab Res Rev. 2012;28(8):692–7.
15.
PapanasNZieglerD. Polyneuropathy in impaired glucose tolerance: is postprandial hyperglycemia the main culprit? a mini-review. Gerontology. 2013;59(3):193–8.
16.
BongaertsBWRathmannWKowallB. Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy: the KORA F4 study. Diabetes Care. 2012;35(9):1891–3.
17.
NémethNPutzZIstenesI. Is there a connection between postprandial hyperglycemia and IGT related sensory nerve dysfunction?Nutr Metab Cardiovasc Dis. 2017;27(7):609–14.
18.
VinikAIMaserREZieglerD. Neuropathy: the crystal ball for cardiovascular disease?Diabetes Care. 2010;33(7):1688–90.
19.
BrownriggJRde LusignanSMcGovernA. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart. 2014;100(23):1837–43.
20.
PafiliKPapanasN. Letter to the editor regarding: diabetic peripheral neuropathy as a predictor of asymptomatic myocardial ischemia in type 2 diabetes mellitus: a cross-sectional study. Adv Ther. 2016;33(10):1848–52.
21.
BaltzisDRoustitMGrammatikopoulouMG. Diabetic peripheral neuropathy as a predictor of asymptomatic myocardial ischemia in type 2 diabetes mellitus: a cross-sectional study. Adv Ther. 2016;33(10):1840–7.
22.
ZieglerDZentaiCPPerzS; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care. 2008;31(3):556–61.
23.
RathmannWZieglerDJahnkeMHaastertBGriesFA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 1993;10(9):820–4.
24.
Pop-BusuiREvansGWGersteinHC; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(7):1578–84.
25.
PapanasNPafiliKMaltezosE. Charcot osteoarthropathy and coronary artery disease in diabetes: the twilight of innocence?Acta Diabetol. 2016;53(1):123–4.
26.
McGillMMolyneauxLSpencerRHengLFYueDK. Possible sources of discrepancies in the use of the Semmes-Weinstein monofilament. Impact on prevalence of insensate foot and workload requirements. Diabetes Care. 1999;22(4):598–602.
27.
PapanasNZieglerD. New vistas in the diagnosis of diabetic polyneuropathy. Endocrine. 2014;47(3):690–8.
28.
ManesCPapanasNExiaraT. The indicator test neuropad in the assessment of small and overall nerve fibre dysfunction in patients with type 2 diabetes: a large multicentre study. Exp Clin Endocrinol Diabetes. 2014;122(3):195–9.
29.
TavakoliMQuattriniCAbbottC. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care. 2010;33(8):1792–7.
30.
AsgharOPetropoulosINAlamU. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care. 2014;37(9):2643–6.
31.
AzmiSFerdousiMPetropoulosIN. Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes. Diabetes Care. 2015;38(8):1502–8.
32.
TavakoliMBegumPMcLaughlinJMalikRA. Corneal confocal microscopy for the diagnosis of diabetic autonomic neuropathy. Muscle Nerve. 2015;52(3):363–70.
33.
StranieriAAbawajyJKelarevAHudaSChowdhuryMJelinekHF. An approach for Ewing test selection to support the clinical assessment of cardiac autonomic neuropathy. Artif Intell Med. 2013;58(3):185–93.
34.
PafiliKTrypsianisGPapazoglouDMaltezosEPapanasN. Simplified diagnosis of cardiovascular autonomic neuropathy in type 2 diabetes using Ewing’s battery. Rev Diabet Stud. 2015;12(1-2):213–9.
35.
YeatsWB. Brown Penny. In: YeatsWB, ed. The Collected Poems. London, UK: Macmillan; 1969:109–110.
36.
KöreiAEIstenesIPapanasNKemplerP. Small-fiber neuropathy: a diabetic microvascular complication of special clinical, diagnostic, and prognostic importance. Angiology. 2016;67(1):49–57.
37.
PutzZTabákAGTóthN. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care. 2009;32(1):181–3.
38.
OroszABaczkóINyiratyS. Increased short-term beat-to-beat QT interval variability in patients with impaired glucose tolerance. Front Endocrinol (Lausanne). 2017;8:129.
